5 ESSENTIAL ELEMENTS FOR ABBV-744 DRUG DEVELOPMENT PROGRESS AND TIMELINE

In Segment C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will acquire treatment right until disease progression or perhaps the contributors are unable to tolerate the study drugs.- Participant consumed grapefruit or grapefruit items within three days before the ve